Tuesday, July 16, 2019 Daily Archives

Commercialization Frameworks for the Biopharma Ecosystem

by

Kiran Chin, managing partner and CEO, MKA Insights Chin began her presentation by introducing her company and its focus on helping bioprocess, life sciences, clinical diagnostics, and gene therapy companies accelerate growth. Although there is no shortage of information on data processes, Chin has found that many companies lack focus on some fundamentals that drive commercialization strategies. Companies tend to dive in without asking basic questions: Why do we exist? What are our capabilities? What is the technology that we…

July 16, 2019

Industry’s Uptake of Single-Use Technology and How it Has Driven Vendor Consolidation: A Business Journalist’s Point of View

by

Dan Stanton, editor, BioProcess Insider technologies (SUTs), exploring the biopharmaceutical industry’s uptake of SUTs and placing that in context of a current forecasting conundrum. Twenty years ago, the demand for cell culture capacity exceeded available supply, and that played a large role in generating investment into biomanufaturing capacity over the following two decades. In 2002, biological blockbusters were emerging, yet the industry was slow to respond. Demand outstripped capacity, leading to large investments into building up the latter. Between 2002…

July 16, 2019

Gilead CA site to house viral vector plant for Kite

by

Kite will build a 67,000 square-foot facility within its parent company’s site in Oceanside, California to ensure sustainable viral vector supply for its cell therapy products. The Oceanside site will advance viral vector development and supply for both Yescarta (axicabtagene ciloleucel) and its pipeline therapies, according to Kite spokesperson Shant Salakian. “This new facility in Oceanside, CA will be dedicated to the manufacturing of viral vectors and will help ensure we have the capabilities to support a robust and sustainable…

July 16, 2019

Boehringer to buy cancer vaccine firm AMAL for €325m

by

The acquisition will be the latest boost for Boehringer Ingelheim in the immune cell-directed therapy space, adding a fusion protein platform and a colorectal cancer vaccine candidate. AMAL’s lead candidate is ATP128, a vaccine in development for stage IV colorectal cancer. The candidate, set to enter the clinic this month, is based on AMAL Therapeutic’s KISIMA technology platform, which brings together three components into a fusion protein used as a vaccine. These are a cell-penetrating peptide for antigen delivery, a…

July 16, 2019

CDMOs driving drug conjugate innovation, says ADC Bio

by

ADC Bio has completed construction of a cleanroom in Wales, part of an $11 million bioconjugation facility set to serve the robust demand for antibody-drug conjugate (ADC) services. The completion of the clean room forms part of the original secured investment for the construction of an $11 million (€9.8 million) bioconjugation facility at ADC Bio’s new site in Deeside, North Wales, UK. “Production is scheduled to commence once the entire bioconjugation facility has received it GMP accreditation from the MHRA,…

July 16, 2019